🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12430 total CTIS records — a stated recency window, not the full historical archive. Synced 17 Sep 2026, 08:35 UTC
2500
Shown in this register
most recently authorised
12,430
Total on CTIS
full historical archive
747
Phase III
within the shown window
Top member states
Spain 1023 France 891 Germany 862 Italy 741 Poland 589 Netherlands 528
Narrow the register
Phase
Phase I 560 Phase I/II 214 Phase II 724 Phase III 747 Phase IV 255
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 49 Pfizer Inc. 45 Novartis Pharma AG 43
Member state
Spain 1023 France 891 Germany 862 Italy 741 Poland 589 Netherlands 528 Belgium 429 Czechia 326
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…
Novo Nordisk A/S
Cardiovascular Diseases
Czechia
16/09/2026
Phase III
A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
2026-526654-14-01Newly Diagnosed Multiple Myeloma
Janssen Cilag International
Neoplasms
Netherlands, Czechia
16/09/2026
Phase II
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00Non Small Cell Lung Cancer (NSCLC)
Oslo Universitetssykehus HF
Neoplasms
Sweden
16/09/2026
Phase III
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
2025-522393-37-00Autoimmune Hepatitis (AIH)
Amgen Inc.
Digestive System Diseases
Belgium, Netherlands, Portugal
16/09/2026
Phase III
A Phase 3a, observer blind, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with intramuscular administration of ProQuad when administered as a second dose to healthy children aged 15 months to 6 years of age
2025-523274-17-00Measles, mumps, rubella, varicella
GlaxoSmithKline Biologicals
Virus Diseases
Germany
16/09/2026
Phase II
A single-centre, Phase 2, open-label study to investigate ovulation inhibition after the administration of different dosages of dienogest tablets in combination with different dosages of drospirenone tablets with regular intake and after intentional intake errors in healthy premenopausal female participants
2026-526788-39-00Contraception/Pregnancy prevention in healthy subjects
Gedeon Richter Plc.
Reproductive and Urinary Physiological Phenomena
Germany
16/09/2026
Phase III
Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)
2024-519897-38-01complex and rare epilepsy in children aged 8 years and older
Centre Hospitalier Regional De Marseille
Nervous System Diseases
France
15/09/2026
Phase I
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
2025-522707-26-00Advanced HR+/HER- breast cancer
Novartis Pharma AG
Neoplasms
Germany, Italy
15/09/2026
Phase I
Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
2026-525244-14-00Metastatic prostate cancer
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
15/09/2026
Phase IV
Attachment Development and Learning in ADHD: The Role of Dopamine.
2025-525122-35-00Attention-Deficit/Hyperactivity Disorder (ADHD)
UZ Leuven
Mental Disorders
Belgium
15/09/2026
Phase II
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
2026-526207-30-00End stage kindey disease
Aplagon Oy
Not possible to specify
Sweden, Finland
15/09/2026
Phase II
Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00Acute lymphoblastic leukaemia
Fundacion PETHEMA
Neoplasms
Spain
15/09/2026
Phase II
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00Pulmonary Disease, Chronic Obstructive
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Czechia, Poland, Germany
15/09/2026
Phase IV
Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
2025-524829-40-00Severe unipolar depression treated with electroconvulsive t…
Varsinais-Suomen hyvinvointialue
Mental Disorders
Finland
15/09/2026
Phase IV
REconsidering Long-TErm ASpirin in the Elderly in Secondary Prevention of Coronary Artery Disease (RELEASE) Norway: A Randomised, Registry-based Trial
2026-526941-91-00Chronic coronary syndrome
Vestre Viken HF
Circulatory and Respiratory Physiological Phenomena
Norway
15/09/2026
Phase I
Detection of rEPO using Dried Blood Spot (DBS)
2026-526613-29-01healthy participants
Consorci Mar Parc De Salut De Barcelona
Not possible to specify
Spain
15/09/2026
Phase II
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
2025-524655-30-00Parkinson’s disease
H. Lundbeck A/S
Nervous System Diseases
Czechia, Spain, Italy, Germany, Sweden
15/09/2026
Phase II
Optimization of De-EscalatiON strategies in early breast cancer
2026-527524-27-00breast cancer
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Neoplasms
Italy
14/09/2026
Phase I
Study of the distribution of linezolid in the prostate in patients who underwent endoscopic prostate enucleation – DiProLine
2026-527015-42-00A Study of the Distribution of Linezolid in the Prostate in…
Centre Hospitalier Le Mans
Male Urogenital Diseases
France
14/09/2026
Phase I
Comparative bioavailability study of Colistin Cyclops® administered as 3 different doses
2025-524657-14-00No therapeutic indication in the current bioavailability tr…
CCDRD Cooperative Clinical Drug Research and Development AG, PureIMS B.V.
Respiratory Tract Diseases
Bulgaria
14/09/2026
Phase III
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…
Grifols Therapeutics LLC
Immune System Diseases
Italy, Poland, Czechia, Spain
14/09/2026
Phase I/II
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
2026-526797-16-00Obesity and overweight
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands
14/09/2026
Phase I
A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid Malignancies
2026-526215-10-00Refractory or Relapsed Solid Malignancies
Fileclo Sp. z o.o.
Neoplasms
Poland
14/09/2026
Phase I
A study to evaluate how well linaprazan glurate is absorbed and how it controls stomach acid (Part I) and investigation of the influence of a meal on the blood levels of linaprazan glurate (Part II) in healthy volunteers
2026-527465-30-00Healthy volunteer
Cinclus Pharma Holding AB (publ)
Bacterial Infections and Mycoses
Germany
14/09/2026
Phase II
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)
2025-524496-23-00Papulopustular Rosacea (PPR)
Novartis Pharma AG
Skin and Connective Tissue Diseases
Bulgaria, France, Germany
14/09/2026
Rows per page Showing 1–25 of 2500
1 2 3 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.